According to an article authored by Michael Gibney, Healthcare Reporter, S&P Global Market Intelligence and published by S&P Global Market Intelligence on June 15, 2020, for some biotech and pharmaceutical companies ready to send new drugs out into the world, the coronavirus pandemic has caused a shift in drug launch practices from face-to-face interactions to virtual communication.
To read the full article from S&P Global Market Intelligence, click here.